Radiation Therapy & Immunity in Pancreatic Cancer

Author profile photo
Radiation Therapy & Immunity in Pancreatic Cancer

Radiation therapy doesn’t just attack pancreatic tumors directly — it also reshapes the immune system, sometimes helping it fight cancer and sometimes holding it back. High-dose radiation can trigger “immunogenic cell death,” a process that exposes tumor antigens and can prime the immune system to recognize cancer cells. At the same time, radiation can lower white blood cell counts (a condition called lymphopenia) and encourage immune-suppressing cells to gather around the tumor. New research from 2024–2026 is mapping out exactly when radiation helps immunity and when it hurts it — and that balance is now shaping how radiation is combined with immunotherapy drugs.

10 Quick Facts: Radiation Therapy and Immunity in Pancreatic Cancer

  1. Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, despite being less common than many other cancers.
  2. Radiation can trigger immunogenic cell death, which releases tumor antigens that may help the immune system recognize cancer cells it previously ignored.
  3. That same radiation can also cause lymphopenia — a drop in circulating lymphocytes — which several studies link to worse survival in locally advanced pancreatic cancer.
  4. Stereotactic body radiation therapy (SBRT) uses fewer, more targeted sessions and appears to be gentler on circulating immune cells than older, longer radiation schedules.
  5. Immune checkpoint inhibitors used alone have a response rate below 5% in most pancreatic cancer patients, which is why researchers are pairing them with radiation.
  6. In mouse studies, radiation has been shown to push tumor-associated macrophages toward an immune-suppressive “M2-like” state that can blunt radiation’s own benefits.
  7. Intraoperative radiation therapy (IORT), delivered directly during pancreatic surgery, has been linked to measurable increases in anti-tumor immune activity afterward.
  8. In the phase 2 CheckPAC trial, combining SBRT with nivolumab and ipilimumab produced a clinical benefit in 37.2% of patients with refractory metastatic pancreatic cancer, versus 17.1% with SBRT and nivolumab alone.
  9. Common immune-related side effects of radiation include fatigue and lowered blood counts, which the American Cancer Society notes usually fade within weeks of finishing treatment.
  10. Newer trials are testing very low radiation doses specifically to “activate” the immune microenvironment without the suppressive effects of higher doses, rather than to shrink the tumor directly.

How Radiation Therapy Works Against Pancreatic Tumors

Radiation therapy uses high-energy beams to damage the DNA of cancer cells so they can no longer divide. For pancreatic cancer, it’s most often delivered as external beam radiation, with stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT) now the most common approaches because they concentrate the dose on the tumor while sparing the stomach, duodenum, and small bowel nearby.

For decades, radiation’s job was understood narrowly: kill as many tumor cells as possible while staying under the radiation tolerance of neighboring organs. That picture has changed. Researchers now describe radiation as having a second job — reshaping how the immune system “sees” the tumor.

The Double-Edged Sword: How Radiation Affects Your Immune System

This is the central tension that recent research keeps coming back to: radiation can activate anti-tumor immunity and suppress it, sometimes in the same patient, sometimes with the same dose.

The Activating Effect

When radiation kills tumor cells, it doesn’t just remove them — it can do so in a way that alerts the immune system. This is called immunogenic cell death. Dying cells display signals on their surface that attract immune cells, and release proteins that help the body’s dendritic cells “present” tumor antigens to T cells. A 2025 review in Frontiers in Immunology describes this as the potential to shift a tumor’s immune profile from “cold” (largely invisible to the immune system) to “hot” (actively infiltrated by immune cells) — the rationale behind most radiation-immunotherapy combination trials.

Radiation delivered during surgery (IORT) appears to support this effect directly in humans: a study of patients who received IORT found changes in blood immune cell populations and cytokine levels consistent with an activated anti-tumor immune response after treatment.

The Suppressive Effect

The same radiation can work against the immune system in several ways:

  • Lymphopenia. Radiation passes through circulating blood on its way to the tumor, and lymphocytes are highly radiosensitive. A study of patients with locally advanced pancreatic cancer found that more severe lymphopenia after chemoradiation was associated with shorter survival.
  • Macrophage reprogramming. In mouse models of pancreatic cancer, radiation increased the proportion of tumor-associated macrophages showing an immune-suppressive “M2-like” profile, which dampened T-cell-driven anti-tumor responses and, in that model, even accelerated progression of pre-invasive lesions.
  • A protective stroma. Pancreatic tumors are surrounded by dense scar-like tissue (desmoplastic stroma) that already blocks immune cells from reaching cancer cells. Some evidence suggests radiation can reinforce this barrier rather than clear it.
  • Regulatory T cells and myeloid-derived suppressor cells. These immune-dampening cell types can expand in and around irradiated tissue, counteracting the antigen-release benefits described above.

Reviewing the current evidence, researchers writing in Frontiers in Immunology frame radiotherapy’s immune effect in pancreatic cancer as a genuine balancing act — capable of converting an immunologically “cold” tumor into a “hot” one, but only under the right dose, timing, and sequencing conditions.— Xu Y, Chen J, Qiu Y, Du J. Frontiers in Immunology, 2025. Read the full review.

What New Research Reveals (2024–2026)

Several recent studies and trials are directly relevant to anyone trying to understand where this field stands right now:

SBRT appears gentler on the immune system than older radiation schedules

A study comparing SBRT to conventional chemoradiation in unresectable pancreatic cancer found that SBRT’s shorter courses and smaller treatment volumes reduced the severity of radiation-induced lymphopenia compared to longer, lower-dose-per-session regimens — a meaningful finding given that lymphopenia has repeatedly been linked to worse outcomes.

Combining radiation with checkpoint inhibitors shows modest but real benefit

The randomized phase 2 CheckPAC trial tested SBRT (15 Gy) combined with the checkpoint inhibitors nivolumab, with or without ipilimumab, in patients with refractory metastatic pancreatic cancer who had already gone through standard chemotherapy. The three-drug combination (SBRT plus nivolumab plus ipilimumab) produced a clinical benefit rate of 37.2%, compared with 17.1% for SBRT plus nivolumab alone — a result the trial investigators, led by Dr. Inna M. Chen at Copenhagen University Hospital–Herlev, called clinically meaningful in a historically treatment-resistant population, while noting that SBRT’s individual contribution to the effect remains unclear and needs further study.

Fraction size and timing matter more than total dose

Preclinical and translational research increasingly suggests that how radiation is split into sessions — not just the total amount delivered — determines whether the immune-activating or immune-suppressing pathway dominates. Very large single doses can trigger enzymes that shut down the signaling pathway immune cells rely on to get “primed,” while smaller, repeated doses tend to preserve that signaling.

Low-dose radiation as an immune “primer” rather than a tumor killer

A newer approach being tested in an active clinical trial uses very low-dose radiation (2 Gy) specifically to activate the tumor’s immune microenvironment, paired with a PD-1 inhibitor and standard chemotherapy, rather than relying on radiation’s cell-killing effect alone. The trial is currently recruiting patients with advanced pancreatic cancer.

FactorConventional Chemoradiation (IMRT)Stereotactic Body Radiotherapy (SBRT)
Typical schedule5 days/week over several weeksUsually 3–5 sessions total
Dose to circulating bloodHigher cumulative exposureLower, due to shorter course
Radiation-induced lymphopeniaMore frequent and more severeGenerally less severe
Immunogenic cell death potentialPresent, spread over more sessionsStrong per-session effect
Typical pairing with immunotherapyLess commonly combinedIncreasingly tested in combination trials

Common Immune-Related Side Effects of Radiation Therapy

Separate from the research on tumor immunology, radiation therapy for pancreatic cancer has well-documented effects on how patients feel and on standard blood work. According to the American Cancer Society, these commonly include:

  • Fatigue, which tends to build gradually over the course of treatment
  • Lowered blood counts, including white blood cells, which can raise infection risk
  • Mild skin reactions at the treatment site
  • Digestive symptoms such as nausea or loose stools, depending on the treatment field

Most of these effects ease within a few weeks of finishing treatment, but your care team will typically monitor blood counts throughout therapy and may adjust the schedule if counts drop too low.

Why This Matters for Treatment Planning

The practical takeaway from this research isn’t that radiation is “good” or “bad” for the immune system — it’s that the relationship is dose-, timing-, and technique-dependent, and oncology teams are increasingly factoring this in when sequencing radiation with immunotherapy or chemotherapy. Centers such as MD Anderson’s radiation oncology research program are actively studying how to tilt that balance toward immune activation, including through newer techniques like FLASH radiotherapy. If you or a loved one are weighing radiation as part of a pancreatic cancer treatment plan, it’s worth asking your oncology team directly how they expect it to interact with any immunotherapy or chemotherapy you’re also receiving.

Frequently Asked Questions

Does radiation therapy weaken the immune system in pancreatic cancer patients?

It can. Radiation frequently causes lymphopenia — a drop in circulating white blood cells — because lymphocytes are very sensitive to radiation exposure as they pass through treated blood vessels. More severe lymphopenia has been linked to worse outcomes in some studies, which is part of why newer radiation techniques aim to minimize it.

Can radiation therapy also help the immune system fight pancreatic cancer?

Yes. Radiation can trigger immunogenic cell death, a process that exposes tumor antigens and can help the immune system recognize cancer cells. This effect is the basis for ongoing trials combining radiation with immunotherapy drugs.

Is SBRT better than conventional radiation for preserving immune function?

Research comparing the two suggests SBRT’s shorter, more targeted courses are associated with less severe radiation-induced lymphopenia than longer conventional chemoradiation schedules, though both approaches carry some immune-related effects.

Can radiation therapy be combined with immunotherapy for pancreatic cancer?

It’s being actively studied. The CheckPAC trial found that SBRT combined with nivolumab and ipilimumab produced a clinical benefit in over a third of patients with refractory metastatic pancreatic cancer, and newer trials are testing low-dose radiation specifically as an immune-activating partner for checkpoint inhibitors.

What are the most common immune-related side effects of radiation for pancreatic cancer?

Fatigue and lowered blood counts are the most common, according to the American Cancer Society. These effects typically resolve within a few weeks after treatment ends, though your care team will monitor blood counts throughout.

Medical disclaimer: This article summarizes published research and is intended to help you ask informed questions — not to replace guidance from your oncologist or radiation oncology team. Pancreatic cancer treatment plans are highly individualized, and how radiation will affect your immune system depends on your specific diagnosis, overall health, and treatment combination. Please discuss any treatment decisions with your medical team.